Create Medicines
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Technology Sq Ste 203, Cambridge, Ma...Website
www.createmedicines.comRevenue
$9.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Create Medicines
CREATE Medicines is a clinical-stage biotechnology company developing in vivo immune programming therapies using its proprietary mRNA-LNP platform. The company focuses on engineering immune cells directly inside the body, including T cells, NK cells, and myeloid cells, to create scalable, repeat-dose, off-the-shelf immunotherapies. Its pipeline targets oncology and autoimmune diseases through RNA based CAR approaches designed to improve accessibility, reduce complexity, and enable programmable immune responses for patients.Explore more
Create Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Create Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Create Medicines has new funding data
Congratulate Masked Content for being promoted to Masked Content at Create Medicines
Check if Create Medicines has recently received funding, and reach out quickly before it becomes old news!
Click to see if Create Medicines had a recent Job posting/layoffs
Earning: See what the market has to say on Create Medicines recently announced quarterly report
Check out if Create Medicines is spiking on competitors!
Create Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Create Medicines launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Create Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Create Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Create Medicines.
Create Medicines financials insights
Gather financial insights about Create Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Seed
$12M
2026
Series B
$122M
Most Recent Scoops
Funding
Funding
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Create Medicines News & Media
CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Appointments come as CREATE advances CRT-402, its lead in vivo CD19 CAR-T program, to clinical development for B cell-driven autoimmune disease CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo...CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Financing to support advancement of CREATE's repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its dual CAR CD19 x BCMA program, and continued progress across the oncology portfolio Round co-led by existing investors Newpath...CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by CREATE's proprietary in vivo CAR clinical dataset, the industry's largest to date CAMBRIDGE, Mass., April...CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components Demonstrating CREATE's leadership in in vivo immune cell engineering across T cells, NK cells, and myeloid cells CAMBRIDGE, Mass., April 17, 2026...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Create Medicines
Sign Up For FreeTo access detailed company insights
CREATE Medicines is a clinical-stage biotechnology company developing in vivo immune programming therapies using its proprietary mRNA-LNP platform. The company focuses on engineering immune cells directly inside the body, including T cells, NK cells, and myeloid cells, to create scalable, repeat-dose, off-the-shelf immunotherapies. Its pipeline tar... Read More
